Growth hormone secretagogues — pulsatile GH release, IGF-1, and the anti-ageing evidence base

Growth hormone (GH) is a 191-amino acid polypeptide secreted by somatotroph cells of the anterior pituitary in a pulsatile pattern. The pulsatile architecture matters: GH is not secreted continuously but in discrete bursts, primarily during slow-wave sleep and following exercise and fasting. Between pulses, GH levels fall to near-zero. This pulsatile pattern — high peaks followed by complete troughs — is what GH-sensitive tissues evolved to respond to, and it is what maintains receptor sensitivity and appropriate downstream IGF-1 regulation.

Age-related growth hormone decline (somatopause) is one of the most consistent changes in endocrine function with ageing. By the seventh decade, GH pulse amplitude is approximately 50% of young adult values, and the area under the GH curve over 24 hours declines by up to 75%. This decline parallels changes in body composition, exercise capacity, sleep architecture, skin integrity, and bone density — driving research interest in whether restoring GH pulsatility can reverse aspects of this functional decline.

Secretagogues versus exogenous GH

The pharmacological approach to GH decline bifurcates at a fundamental mechanistic choice: replace GH exogenously, or stimulate the pituitary to produce more of its own.

Exogenous recombinant human GH (rhGH) administration overrides the pulsatile pattern entirely. Subcutaneous GH injection produces a pharmacokinetic peak followed by slow decline — a non-physiological pattern that maintains GH receptor activation more continuously than natural pulses do. The consequences include progressive IGF-1 elevation (which can reach supraphysiological levels), insulin resistance through GH's anti-insulin effects on peripheral tissues, and GH receptor downregulation through continuous activation. Long-term high-dose exogenous GH also carries concerns about IGF-1-driven cell proliferation in susceptible tissues.

GH secretagogues — peptides that act on the hypothalamic-pituitary axis to stimulate endogenous GH release — work upstream of these effects. By amplifying the pituitary's natural pulsatile release rather than bypassing it, secretagogues preserve the trough-to-peak pulse architecture and maintain the negative feedback systems (somatostatin, IGF-1 feedback on the pituitary) that prevent excessive IGF-1 elevation. The result is larger natural pulses rather than continuous exogenous GH exposure.

The somatotroph response to secretagogue stimulation

Somatotroph cells of the anterior pituitary integrate signals from two primary receptor types: the GHRH receptor (which drives cAMP-mediated GH synthesis and priming) and the ghrelin receptor GHS-R1a (which drives calcium-mediated GH granule release). The combination of GHRH receptor agonism (CJC-1295) and ghrelin receptor agonism (Ipamorelin) produces synergistic stimulation of GH release — larger pulses than either compound alone produces, because the two pathways are sequential and complementary rather than redundant.

This receptor pharmacology is covered in detail in the dedicated CJC-1295/Ipamorelin article. The relevant point in the anti-ageing context is that the secretagogue combination restores a physiological-appearing GH pulse architecture rather than imposing a pharmacological GH curve — which is precisely what makes the chronic safety and tolerability profile of secretagogues more favourable than exogenous GH for long-term anti-ageing protocols.

IGF-1 as the downstream mediator

Most of GH's anti-ageing effects — improved lean mass, reduced adiposity, improved bone density, skin collagen synthesis, cognitive function — are mediated not by GH directly but through IGF-1 produced by the liver in response to GH stimulation. GH also stimulates local IGF-1 production in peripheral tissues including muscle and bone.

IGF-1 promotes protein synthesis in muscle (through mTORC1 activation), inhibits protein catabolism, stimulates satellite cell proliferation for muscle repair, promotes osteoblast activity in bone, supports neurogenesis in the hippocampus, and has direct anti-apoptotic effects in multiple tissue types. The age-related decline in IGF-1 (parallel to the decline in GH pulse amplitude) is a significant contributor to sarcopenia, osteopenia, and the reduced regenerative capacity of aged tissues.

Secretagogue protocols produce gradual, moderate increases in serum IGF-1 — significantly smaller than exogenous rhGH doses produce. This moderation is a safety feature: the risk of supraphysiological IGF-1 and its associated proliferative concerns is substantially lower with secretagogues than with exogenous GH.

Body composition and longevity data

The clinical literature on GH secretagogues in older adults is primarily body composition data. Studies using GHRH analogues and combined GHRH/ghrelin receptor agonist protocols in adults over 60 consistently show improved lean mass to fat mass ratios, increased bone mineral density, and improvements in physical performance metrics. These outcomes are smaller in magnitude than exogenous GH produces but are achieved without the insulin resistance and IGF-1 excess concerns associated with pharmacological GH replacement.

The longevity connection is indirect but mechanistically plausible: sarcopenia is a significant predictor of frailty and mortality in older adults, and interventions that preserve muscle mass and bone density may translate to reduced fall risk, better metabolic health, and improved quality of life — the functional endpoints that matter for healthy ageing research.

Research-grade GH secretagogue peptides including CJC-1295, Ipamorelin, and combination formulations are available through RetaLABS with full HPLC purity and mass spectrometry documentation for preclinical research applications.

The GH secretagogue framework occupies a pharmacologically rational position in the anti-ageing research space: it addresses a well-documented age-related endocrine decline through a mechanism that preserves rather than overrides the physiological pulse architecture, and the body composition data in older adults supports the directional hypothesis that restoring GH pulsatility contributes to the functional outcomes that define healthy ageing.